Founder
Dr. Holtzman is Founder and President of NuPeak Therapeutics. His research focuses on epithelial barrier cells, both as triggers and targets of the immune response, particularly in the airway, with 466 reports on this topic. He assembled an outstanding drug discovery and development team at NuPeak based on an extensive resume for leadership in scientific and business activities. His academic career includes 30 years as the Director of Pulmonary and Critical Care Medicine, Selma and Herman Seldin Distinguished Professor of Medicine, and Professor of Cell Biology and Physiology at Washington University. He obtained a B.A. and M.D. with honors from Northwestern University School of Medicine, Residency in Medicine at Duke University, and Fellowship and the Faculty positions in Pulmonary and Critical Care Medicine at the University of California, San Francisco.
Director Clinical Development
Dr. Broschat has over 30 years of clinical research experience in the pharmaceutical and medical device space. She has applied her skills in leadership positions at Pfizer, Sanofi, and Bristol-Meyers Squibb and as a part of the BioGenerator biotech incubator in St. Louis. Her areas of expertise include early drug discovery and clinical trial design and management that are vital to NuPeak development strategy. Dr. Broschat received a Ph.D. in Biochemistry from Ohio State University.
Director Business Development
Dr. Montgomery is a highly accomplished entrepreneur as a biotech founder and director. His resume includes leadership positions at Genentech and Gilead and then a series of biotech companies (PathoGenesis, Corus, Cardeas, and Avalyn) that led to new therapeutics and highly successful exits. For his accomplishments, he has received numerous awards including the Commissioner’s Special Citation from the U. S. Food and Drug Administration. His work has focused on. the development and application of inhaled drug delivery for lung diseases. He will continue to provide this expertise to NuPeak in research and business development activities. Dr. Montgomery earned a B.S. in Chemistry and M.D. both with honors and then Medicine Residency at the University of Washington followed by Fellowship in Pulmonary and Critical Care Medicine at University of California, San Francisco with mentorship from Dr. Holtzman.
Director TABA Development
Dr. Redmann is an entrepreneur and scientist who has worked on over 40 commercialization/business plans used for fund-raising efforts. She was recruited to NuPeak to construct the commercialization plan for the successful DOD and NIH STTR Phase II awards. She now serves in a TABA advisor role that includes assistance in each aspect of the scientific and business development of the STTR project and NuPeak activities in general. Dr. Redman obtained her B.S. from Randolph College. Ph.D. from Mount Sinai School of Medicine and postdoctoral research training at Washington University in Immunology with close colleagues of Dr. Holtzman.
Advisor Inhalation Tox
Dr. Reed is highly experienced in the field of aerosolized drug development. He has worked in the inhaled toxicology field for 20 years, including VP of Applied Toxicology and Nonclinical Development at Lovelace Biomedical and currently as the CEO of Coelus, CSO at Nob Hill Therapeutics, and VP at Kinnear Pharmaceuticals. He has served as a consultant to NuPeak for the past 4 years providing input on inhaled pharmacology, toxicology, and regulatory activities. His activities in these fields has also provided key business connections to CRO and CDMO activities for CMC and device application for NuPeak. Dr. Reed received his B.A. in Biology and Ph.D. in Pharmacology and Toxicology from Texas A&M University and postdoctoral training at MD Anderson and University of New Mexico.
Director Clinical Provider
Dr. Reiss has over 30 years of experience in the pharmaceutical industry, including leadership positions at Merck, Celgene, Novartis, and Covance. His team at Merck was responsible for the clinical development and approval of Montelukast for asthma. In addition, he has served as CMO at Repertoire Immune Medicines, SAB member at Koneska, and venture partner at Novo Ventures. Thus, Dr. Reiss has broad expertise in drug development from medical and financial activities leading to successful human clinical trials. He maintains a longstanding role in these activities at NuPeak. Dr. Reiss obtained a B.A. from the University of Pennsylvania, M.D. from Vanderbilt University, Medicine Residency at Columbia-Presbyterian, and then Fellowship in Pulmonary and Critical Care Medicine at the University of California, San Francisco, again with mentorship from Dr. Holtzman.
Director Med Chem
Dr. Romero is an outstanding medicinal chemist who was recruited to Washington University 10 years ago to direct Medicinal Chemistry for the project. His work resulted in promotion to Professor of Medicine and then transition to NuPeak. During his 25-year experience, he has performed medicinal chemistry research in pursuit of clinical candidates for neuroscience, antibacterial, antiviral, and inflammation targets, contributing to the discovery of eight clinical candidates, including three that progressed into Phase II and III clinical trials. He has also supported several projects as multidisciplinary drug discovery project team leader, led a combinatorial chemistry technology core group, and led several Pharmacia and Pfizer global cheminformatics initiatives. Dr. Romero received his B.S. from Johns Hopkins University, Ph.D. from University of Wisconsin, and Ph.D. from Columbia University.
Director Pharmacol
Dr. Zhang is a highly accomplished molecular biologist and pharmacologist who was recruited Washington University 25 years ago. His outstanding work also resulted in promotion to Professor and then transition to NuPeak. He directed the Molecular and Animal Model Cores that includes capabilities for transgenic mice generation, tobacco smoke, viral and allergen exposures, pulmonary function testing, and pharmacology-toxicology studies. His research publications appeared on the covers of Nature Immunology and the Journal of. Immunology. He has also been responsible for the cell-based and animal-model studies of drug candidates in academic and CRO settings, including his team collaboration with Lonza-Bend and Lovelace Biomedical to establish the dry powder inhalation (dpi) delivery system for animal model and human use. Dr. Zhang received his M.D. from Anhui Medical College and Ph.D. from Albert-Ludwigs University.